Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF
Phase of Trial: Phase IV
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Tocilizumab (Primary) ; Tocilizumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RAFTING
- 07 Jan 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2020.
- 27 Mar 2018 Status changed from not yet recruiting to recruiting.
- 23 Feb 2018 Planned End Date changed from 1 Sep 2021 to 1 Oct 2021.